Twist Bioscience reported a quarterly loss of $0.62 per share, wider than the Zacks Consensus Estimate for a $0.54 loss. The result also improved slightly from a $0.66 loss per share a year ago, but the miss versus expectations is the key takeaway. The update is likely to pressure sentiment modestly, though the headline is limited to EPS and contains no revenue or guidance details.
Twist Bioscience reported a quarterly loss of $0.62 per share, wider than the Zacks Consensus Estimate for a $0.54 loss. The result also improved slightly from a $0.66 loss per share a year ago, but the miss versus expectations is the key takeaway. The update is likely to pressure sentiment modestly, though the headline is limited to EPS and contains no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
